Arena Pharmaceutical's | search
Click here to view Arena Pharmaceutical's news from 60+ newspapers.
Bookmark or Share- Pfizer to Acquire Arena Pharmaceuticals | PfizerPfizer to Acquire Arena Pharmaceuticals. copy Open in tab. Proposed acquisition offerspotentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases. Expands innovative pipeline potentially enhancing growth through 2025 and beyond.
- Pfizer Completes Acquisition of Arena PharmaceuticalsArena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including ulcerative ...
- Arena, completing its turnaround, sells to Pfizer for nearly $7 billion ...Pfizer has agreed to acquire Arena Pharmaceuticals for about $6.7 billion in a deal that validates the San Diego biotech’s plan to reshape itself around a portfolio of inflammation drugs. Pfizer will buy Arena for $100 per share in cash, more than double the biotech’s closing price on Friday.
- Pfizer finalizes $6.7 billion acquisition of Arena Pharmaceuticals ...Michael Walter | March 14, 2022 | Cardiovascular Business | Economics. Pfizer has completed its $6.7 billion acquisition of Arena Pharmaceuticals, finalizing a deal that involves multiple cardiovascular properties. The transaction was first announced back in December 2021.
- Arena Pharmaceuticals Company Profile - CraftCompany Summary. Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing drugs that target G protein-coupled receptors (GPCRs). Its investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation ...
More
